Liquidia Co. (NASDAQ:LQDA) Insider Sells $25,108.60 in Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,260 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the transaction, the insider now owns 207,383 shares in the company, valued at $2,304,025.13. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Rajeev Saggar also recently made the following trade(s):

• On Friday, July 19th, Rajeev Saggar sold 1,873 shares of Liquidia stock. The stock was sold at an average price of $11.13, for a total transaction of $20,846.49.

Liquidia Price Performance

Shares of NASDAQ:LQDA traded up $0.25 during trading on Tuesday, reaching $11.38. 772,491 shares of the company’s stock traded hands, compared to its average volume of 1,004,987. Liquidia Co. has a 12 month low of $5.71 and a 12 month high of $16.99. The company has a 50 day moving average of $10.40 and a 200-day moving average of $12.00. The stock has a market capitalization of $869.59 million, a P/E ratio of -7.20 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The business had revenue of $3.66 million for the quarter, compared to the consensus estimate of $7.92 million. Equities research analysts predict that Liquidia Co. will post -1.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on LQDA shares. Lifesci Capital started coverage on shares of Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price for the company. Needham & Company LLC reissued a “buy” rating and issued a $25.00 target price on shares of Liquidia in a research report on Monday, August 19th. Bank of America dropped their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. HC Wainwright dropped their target price on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Finally, Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System boosted its stake in Liquidia by 491.2% during the 1st quarter. California State Teachers Retirement System now owns 46,181 shares of the company’s stock valued at $681,000 after purchasing an additional 38,369 shares during the period. BNP Paribas Financial Markets boosted its stake in Liquidia by 119.4% during the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after purchasing an additional 125,315 shares during the period. Swiss National Bank acquired a new position in Liquidia during the 1st quarter valued at about $1,325,000. Boston Partners acquired a new position in Liquidia during the 1st quarter valued at about $762,000. Finally, Principal Financial Group Inc. boosted its stake in Liquidia by 112.3% during the 1st quarter. Principal Financial Group Inc. now owns 36,462 shares of the company’s stock valued at $538,000 after purchasing an additional 19,288 shares during the period. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).